However, since monotherapy with DNA hypomethylating agent as a first-line treatment for MDS exhibits only a modest clinical efficacy, combination with other targeted therapies is likely to achieve superior efficacy against EVI1-expressing MDS. The gene discussed is RUNX1; the disease is myelodysplastic syndrome.